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Abstract 
‘Accommodation’ refers to a vascularized transplant that has acquired resistance to 
antibody-mediated rejection (AMR). The term was coined in 1990 (1), but the 
phenomenon was first described after clinical ABO-incompatible (ABOi) renal 
transplantation in the 1980s (2) and is recognised as a common outcome in this 
context today. Because of the absence, until recently of reliable animal models of 
allograft accommodation, it has been studied extensively by investigators in the 
xenotransplantation field.  With recent advances in the ability to recognise and 
diagnose AMR in human organs, the growth of desensitization programmes for 
transplantation into sensitised recipients and the availability of therapies that have 
the potential to promote accommodation, it is timely to review the literature in this 
area, identifying lessons that may inform preclinical and clinical studies in the future.  
 
Introduction: Endothelial cell activation and accommodation in 
xenotransplantation. 
The current paradigm of AMR places ‘endothelial cell activation’ at the heart of the 
pathophysiological process. This concept was first explored by Pober and colleagues 
in the 1980s, when defining how cytokines such as IL-1 influenced the interaction 
between endothelium and T cells (3). Extending the idea to humoral processes in 
xenotransplantation, it was proposed that changes in endothelial cell phenotype, 
such as chemokine and cytokine release, change in shape and loss of protective 
molecules (for example anticoagulants) bound to heparan sulphate, were integral to 
the pathology of AMR (1). In the context of pig-to-primate transplantation, the factors 
initiating these changes were primate IgM anti-pig antibodies (Abs) followed by 
complement activation via the classical pathway. Since hyperacute AMR was a 
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significant hurdle in the early 1990s, these and other insights had an important 
influence on subsequent developments in the field.  
Occasionally, pig organs survived and functioned (1, 4) despite the presence of high 
titre xenoreactive Ab in the circulation and complement deposition in the graft (5); 
these organs were described as having ‘accommodated’. Acknowledging that similar 
phenomena had been recognised and described (though not investigated) in clinical 
ABOi and HLA incompatible transplantation (1), Platt et al proposed that engineering 
a state of ‘accommodation’ would be a useful strategy for clinical 
xenotransplantation. Investigations in pursuit of this goal over the last 20 years have 
yielded a significant understanding of the mechanisms involved, though have yet to 
impact clinically. 
Of the three mechanisms originally proposed to explain accommodation (1), the first 
was that endothelial cells developed a resistance to injury during the post-transplant 
period; the second was that Abs post-transplantation had an altered affinity and/or 
specificity for the graft, compared to those pre-transplant and the third suggested 
that the antigenic epitopes on the graft were changed during transplantation, such 
that Ab could no longer bind.  Of these, 1 and 3 refer to changes in the donor organ  
(‘graft accommodation’) whereas 2 describes a change in the recipient (‘host 
accommodation’) and is an example of modulation of the anti-donor immune 
response. 
 
Antibody-mediated rejection in xenotransplantation – the importance of 
complement 
Evidence suggests that complement plays a critical role in xenograft AMR. In some 
rodent models (for instance the discordant guinea pig-to-rat), complement is 
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activated by the alternative pathway (i.e. independently of Abs), though this is 
thought to be unrepresentative of the situation in preclinical pig-to-primate models. 
Two other commonly used rodent models involve transplanting hearts from hamsters 
or mice into rats. These are concordant models; in other words, rats have no pre-
existing anti-mouse or anti-hamster Ab (AHAb), so transplanted hearts are not 
rejected hyperacutely.  Instead, Abs develop by both T-dependent and T–
independent mechanisms resulting in AMR within 3-5 days.  
Ciclosporin (CsA) completely suppresses T cell activation in these models. 
Therefore, CsA-treated rats fail to make T-dependent IgG, but grafts still suffer AMR 
within the first week due to T-independent IgM production (6). However, co-
administration of CsA and cobra venom factor (CVF), to inhibit complement 
activation prevents rejection, and hearts in up to 75% of recipients survive long-term 
(as long as CsA is given), illustrating how important complement-fixation is for AMR 
in these models. Targeting the terminal complement components, using for instance 
a mAb against C6, has the same inhibitory effect as CVF.  Additionally, AMR does 
not occur when hearts are transplanted into C6-deficient rats, indicating that 
preventing assembly of the membrane attack complex is sufficient to inhibit AMR (7). 
This highlights that, of the potential mechanisms through which complement may be 
acting, generation of membrane attack complex is most important (figure 1) and 
early cascade molecules such as the anaphylotoxins C3a/C5a, have little role in 
these models. 
In another model, hearts from Lewis rats are transplanted into recombinase 
activating gene (RAG)- and Galactosyl-transferase double KO mice.  
Galactosyltransferase is the enzyme responsible for catalysing the addition of a 
terminal galactose through an α(1-3) linkage onto the carbohydrate chains of 
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glycoproteins, the moiety identified as the major xenoantigen recognised by human 
anti-pig Abs.  Passive transfer of mAbs against the α(1-3)gal epitope (8) induces 
AMR which is complement-dependent, even when the mAb fixes complement poorly 
in vitro (9) though in these circumstances, innate effector cells and FcR-dependent 
mechanisms are also involved (10) (figure 1).  
In pig-to-primate models, the importance of complement has been established by the 
resistance to AMR offered by organs from transgenic pigs expressing human 
regulators of complement activity (11).  Two points deserve further mention. The first 
is that vascularised pig organs have an enhanced susceptibility to the pathological 
effects of primate complement, not because of the originally proposed ‘homologous 
restriction’ of complement regulators (12), but because of distinct differences in the 
distribution of complement regulators, particularly the membrane attack complex 
inhibitor CD59 in pig vs. primate vasculature (13). This profound lack of regulation is 
not a problem in human allogeneic transplantation, though the strong association 
between AMR and C4d deposition and the recently reported success of the anti-C5 
monoclonal eculizumab in treating clinical AMR indicate that complement activation 
is nevertheless relevant clinically. The second point is that pig organs are susceptible 
to complement-independent AMR which is initiated by anti-pig alone (14, 15), so that 
inhibition of complement in pig-to-primate xenotransplantation is insufficient, without 
other measures, to prevent AMR.  Whether complement-independent AMR occurs in 
human clinical transplantation is a subject of intense interest.  
 
Accommodation in Rodent models 
In the hamster/mouse-to-rat models, complement only needs to be inhibited during 
the first week to prevent AMR (16, 17). An identical ‘naïve’ heart, transplanted after 
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this time undergoes AMR, indicating that the recipient has Abs and complement 
capable of causing rejection (18). Thus the first heart has acquired resistance to 
these Abs and this is classical graft accommodation. There is no complement-
independent AMR in these models;  additionally, accommodated hearts are resistant 
to rejection by passively administered Abs and many survive after re-transplantation 
into CsA-treated rats without CVF (19). Accommodation does not manifest in 
recipients given CVF without CsA, illustrating that effective suppression of T cells 
and elicited T-dependent Ab production is required for accommodation to occur (17, 
19). 
However, as first indicated by Hasan et al, accommodation does not occur when all 
anti-donor Ab production is suppressed (20-22). Moreover, passively transferred Ab 
prevented from causing AMR by CVF, can induce resistance to AMR in hamster 
hearts. Several studies since have shown the same (6, 19, 23-26) and have defined 
conditions in which graft accommodation can be achieved without manipulation of 
complement (23).  All these data are summarised in table 1. The indication is that Ab 
binding to the graft is necessary for graft accommodation.  
Transplanted ‘second’ xenografts grafts can accommodate, but the ease with which 
it happens depends on the context of the initial sensitisation.  Recipients sensitised 
by rejecting a first heart transplanted under cover of CsA (without CVF) develop 
sensitised T-independent B cells and CVF administered at the time of the second 
transplant can promote long-term survival. However, rats sensitised in the absence 
of any immunosuppression sensitise T and B cells and reject a second heart within 
minutes (27) even with CVF.  In these animals, CVF and CsA need to be 
administered together with exchange transfusion prior to the second transplant (to 
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reduce Ab titres) and splenectomy or ciclophosphamide to delay the return of elicited 
Abs.  
Therefore the fundamental condition required to allow spontaneous accommodation 
in these models is controlled exposure of the graft endothelium to anti-donor Ab 
post-transplantation (figure 2). The most logical explanation of why CVF is required 
in many models is that it prevents AMR in the context of rising Ab titres, thus allowing 
time for accommodation to develop.  For the same reason, accommodation is only 
seen when there is adequate suppression of T cell responses. Recent studies in 
allogeneic mouse transplant models have confirmed similar requirements to promote 
the long term survival and accommodation after transplantation into allosensitised 
recipients (28, 29). 
 Alternative models of accommodation 
Transgenic expression of tethered anticoagulants on the endothelium of mouse 
hearts makes them resistant to AMR after transplantation into rats and with CsA, 
they survive long-term without chronic rejection (30).  The resistance is not just due 
to the inhibition of thrombosis, but also to inhibiting thrombin signalling, which inhibits 
local (donor) CCL2 chemokine gradients, without which rat leukocytes are unable to 
infiltrate the organ (31, 32).  The importance or relevance of these data to other 
models of graft accommodation has not been determined.  
 
Phenotype of graft accommodation 
The above data suggests that accommodation is time-dependent and requires a 
specific interaction between the graft endothelium and low titre anti-donor antibodies. 
This section considers the phenotypic changes in the vasculature that result. 
 Reduced expression of antigenic epitopes. 
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Accommodation after leflunomide represents a special case, in that hearts show no 
binding of anti-donor Ab or complement on histology (25), compared to second naïve 
hearts which do (and are rejected by AMR).  Therefore accommodation is due to 
reduced expression of xenoantigens in the graft, most likely due to the direct effect of 
the drug.  
 Enhanced regulation of complement 
Accommodation induced in rat hearts by low titre IgG1 anti-gal Ab is characterised 
by significant upregulation of membrane bound complement regulators decay 
accelerating factor, Crry and CD59 (26), accompanied by increased deposition of the 
C3 breakdown product C3d compared to controls, suggesting enhanced functional 
regulation of complement activation on the donor endothelium. Similar features have 
been defined in accommodated pig organs after transplantation into baboons (33) or 
Galactosyltransferase KO pigs (34). 
Supporting the hypothesis that these changes were due to the anti-donor Ab, the 
accommodating IgG1 anti-gal Ab induced increased expression of the same 
complement regulators by rat endothelial cells in vitro and induced resistance to 
complement-mediated lysis (26). Other groups have reported similar findings using 
porcine endothelial cells in vitro (35), and shown that direct signalling though an 
NfKB-independent pathway is involved (36, 37) in a time-dependent, concentration-
independent manner (38).   
As elegantly demonstrated by Shimizu et al (39), enhanced expression of 
complement regulators on the donor organ increases the threshold for AMR, so this 
aspect of the accommodated phenotype has functional significance and is the basis 
of the resistance to AMR after passive transfer of Ab (and the reason why CVF can 
be stopped after 1 week). However, resistance to AMR induced in this way is relative 
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not absolute, so accommodated hamster hearts are rejected after injection of large 
boluses of AHAb (16), and accommodated rat hearts are sensitive to IgG3 anti-gal 
Ab, which fixes complement more efficiently than the IgG1 (26). These data highlight 
the potential fragility of graft accommodation.  
 Expression of ‘cytoprotective’ proteins 
The vasculature of accommodated mouse hearts show expression of 
hemeoxygenase-1 (HO-1). This single protein is absolutely required for 
accommodation, best illustrated by experiments using HO-1-deficient mice (40). 
Elegant work by Soare’s group has demonstrated the mechanisms by which HO-1 
works, and in this context, carbon monoxide is important (41). Because HO-1 plays a 
role in regulating decay accelerating factor expression by mouse endothelium (42), 
part of its importance in vivo may be through this effect. HO-1 is also upregulated 
during AMR, so it is not a biomarker of the accommodated state. Instead, it appears 
to be critically involved in the cellular response to multiple stress stimuli, so should 
be regarded as permissive for accommodation rather than a specific mediator. 
In accommodated hamster organs other cytoprotective proteins such as A20, Bcl-2 
and Bcl-xL (18, 19, 23, 27, 43) are also found in association with reduced rates of 
apoptosis compared to controls. There is considerable evidence that these proteins 
are induced in vitro in porcine and human endothelial cells by low (but not high) titre 
Abs against multiple epitopes, including MHC (23, 37, 44), by a nitric oxide 
dependent process (45) involving signalling through adenosine A2 receptors (44) 
and AKT (46, 47). This suggests that, unlike for HO-1, these proteins may be 
specifically involved in accommodation. In support of this, BcL-xL expression by 
peritubular and glomerular capillaries has been described as a specific marker of 
accommodation in biopsies taken within the first week after transplantation into HLA-
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sensitised recipients (48). Although the functional importance of these molecules in 
vivo has not been established, they are postulated to limit the vascular response to 
inflammation, by inhibiting NFkB activation. The absence of complement-
independent AMR in rodent and pig-to-primate models, implying suppression of the 
mechanisms driving this type of rejection, would support this hypothesis. 
Other molecules with cytoprotective function have been identified in accommodated 
porcine organs (33) and human ABOi renal transplantation (49), including heparan 
sulfate, syndecan-4-phosphate (both of which interact with anti-inflammatory 
moieties such as antithrombin for example (50)), Muc-1 and members of the tyrosine 
kinase receptor family.  
 
Relationship between graft and host accommodation and immune tolerance. 
In a contrived but elegant allogeneic model involving Galactosyltransferase KO 
mouse recipients, bone marrow reconstitution, injection of memory B cells specific 
for the α(1-3) gal epitope (51-53) and rechallenge with α(1-3) gal epitopes at variable 
times after transplantation of a wild-type heart, host rather than graft accommodation 
was shown to develop, the basis of which was predominant production of IgG2b, 
non-complement fixing antibodies, which bound the graft but did not cause AMR.  
These were dependent on the timing of rechallenge; too early and complement-fixing 
IgG2a were made (causing AMR); too late and anti-gal Ab production was 
completely suppressed indicating the recipient animals had become fully tolerant to 
the α(1-3) gal epitope present on the graft.  These data suggest that host 
accommodation and tolerance are related. 
In this model system, the transferred memory B cells were reliant on (absent) T cell 
help to generate new Abs against the α(1-3) gal epitope, whereas in many 
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xenogeneic models, B cells function independently.  Accordingly, the reports of ‘host 
accommodation’ in xenogeneic systems are limited. Komori et al, using tacrolimus 
and post-transplant splenectomy (day 1) reported that, alongside evidence of graft 
accommodation in hamster hearts, there was a significant reduction in circulating rat 
AHAb levels compared to controls (54).  Because accommodated hearts were 
rejected quickly when re-transplanted into naïve, tacrolimus-treated hosts and 
second naïve hearts were accepted by recipients with an accommodated heart, host 
accommodation was thought to be predominant in this model.  Leflunomide appears 
to promote both graft accommodation and tolerance, depending on it’s length of 
administration; after 4 weeks, it causes permanent suppression of the T-independent 
B cell response (25), so that rats transplanted with a second hamster heart accept 
them without rejection. In contrast, if administered for only two weeks it causes graft 
accommodation (see above). There is evidence from this model that only organs 
showing signs of graft accommodation are adequately protected against chronic 
rejection (55, 56). 
In CVF-based accommodation, host accommodation is less convincing. 
Accommodated hamster hearts may contain rat leukocytes preferentially expressing 
Th-2 cytokines such as IL-4, IL-13 and IL-10 (16), in association with skewing of rat 
IgG subclasses, changes which have been reported to impact favourably on the 
survival of second hearts, suggesting an influence of host accommodation on 
outcomes, but these findings have been contradicted (57).  Nevertheless, in vitro 
studies indicate that porcine endothelial cells incubated with human anti-pig Abs 
induce preferential Th-2 cytokine responses from human T cells (58), though the 
relevance of this in vivo is unclear. In accommodated mouse hearts, the expression 
of HO-1 is potentially capable of several direct effects on the recipient immune 
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system, such as reducing proliferation and IL-2 production and inducing activation-
induced cell death in CD4+ T cells (59, 60), and promoting regulatory T cells (61) 
and isolated HO-1 expression by the donor can influence the host immune response 
(62), but the relevance of these effects has not been established.  
 
Summary and conclusions. 
Rodent and pig-to-primate xenograft models have been used extensively to study the 
phenomenon of accommodation, with the majority of data indicating that 
accommodated grafts have a characteristic phenotype, which can arise 
spontaneously if either systemic complement activation (beyond C5) is transiently 
inhibited or the graft is exposed to slowly increasing titres of Ab. In this context, the 
active resistance to endothelial cell activation that develops involves increased 
expression of complement regulators, to reset the threshold of Ab required to initiate 
AMR, and cytoprotective proteins, postulated to prevent other elements of 
endothelial cell activation, particularly that due to NFkB activation. Organs that 
undergo such changes appear resistant to both AMR and chronic Ab-mediated 
rejection. Previously sensitised T and B cells have a significant impact on the ease 
with which accommodation occurs, so an important and necessary element in all 
accommodation induction protocols is effective control of recipient adaptive 
responses, such that T cell mediated rejection is inhibited and T-dependent B cell 
responses are controlled. 
These insights have obvious relevance for human clinical allotransplantation. The 
shortage of organs is driving increasing numbers of ABOi transplants after which 
accommodation appears to be common. However, few studies have investigated the 
phenotype of these organs and there is a paucity of knowledge about how this 
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important state arises.  Early work showing the continued presence of donor blood 
group antigens (63)  and the presence of C4d deposits in the vasculature of many 
biopsies indicates that the accommodation in these grafts resembles that seen in the 
classical models of xenograft accommodation.  
After HLA desensitisation, accommodation is thought to be uncommon, though it 
was described in a small series of patients from the 1990s (48). These patients 
received pre-transplant cyclophosphamide, sometimes for a prolonged period prior to 
transplantation, an agent rarely used nowadays. Whether this was important is 
difficult to know, but it is a possibility. For the modern day, clinical interventions to 
promote accommodation in this group of patients are now available.  From the 
understanding of xenogeneic systems, the most logical strategy would be to control, 
but not inhibit, the interaction between the graft and circulating Ab in the immediate 
post-transplantation period. The high incidence of C4d+ AMR in these patients 
suggests that inhibition of systemic complement activation for a short period post-
transplantation with Eculizumab would be useful and there are now agents to 
improve control of adaptive responses and to manipulate the induced antibody 
response, by selectively targeting B cells (Rituximab) and/or plasma cells 
(Bortezomib). However, aside from their use in isolated cases (64), all of these have 
yet to be systematically tested in rational protocols designed to promote 
accommodation. 
As there are no validated markers of human accommodation (besides C4d in the 
absence of pathology on the graft biopsy), a major question will be how to recognise 
spontaneous accommodation when it has occurred?. Two other questions are 
important to address if we are to develop ways to engineer accommodation (rather 
than allow it to occur spontaneously). These are what is the mechanism 
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underpinning the resistance to AMR  and do accommodated organs promote 
immune modulation in the recipient? Using the knowledge gained from studying 
xenografts as a place to start, well-designed studies in selected human recipients 
could address these and other important questions. 
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Figure 1 legend  
Diagram to illustrate the potential mechanisms of injury induced by complement 
activation.  In models of xenogeneic AMR, the generation of membrane attack 
complex is most important. 
 
Figure 2 legend 
Diagram to illustrate the events at the endothelium during antibody-mediated 
rejection vs. graft accommodation.  
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Table 1 – Experiments illustrating the role of antibodies in spontaneous accommodation 
 
 
Model 
 
Ref 
 
Immunosuppression 
 
Survival in first 
recipient 
 
XNA response 
Outcome after 
passive transfer 
of anti-donor Ab 
Outcome after re-
transplantation of surviving 
graft into second, CsA-
treated recipient 
 
 
Hamster heart to 
rat 
 
 
18-20 
CsA + CVF 
CsA + 
Ciclophosphamide 
Long-term 
Long-term 
IgM 
None 
No rejection 
AMR 
[NB:If preceded by 
conditioning with 
Ab+CVF – no 
rejection] 
- 
- 
- 
Hamster heart to 
rat 
14 CsA + CVF 
CsA + rapa 
Long-term 
Long-term 
IgM 
None 
- 
- 
Long-term survival 
Rejection  
 
Hamster heart to 
rat 
 
21 
CSA+ splenectomy on 
day: 
-1 
1 or 2 
3 
 
 
Long-term 
Long-term 
AMR 
 
 
None 
Delayed IgM 
IgM 
 
 
AMR 
No rejection 
- 
 
 
- 
- 
- 
 
Hamster heart to 
rat 
 
6,22,23 
CsA* + Leflunomide for: 
5 days 
14 days 
 
AMR 
Long-term 
 
IgM 
Delayed IgM 
 
- 
No rejection 
 
- 
AMR† 
Rat heart to 
RAG-/- GalT-/- 
double KO mice 
Challenged with; 
Low titre IgG1 
 
High titre IgG1 
Low titre IgG3 
 
 
 
 
24 
 
 
 
 
None 
 
None 
None 
 
 
 
 
Long-term 
 
AMR 
AMR 
 
 
 
 
- 
 
- 
- 
 
 
 
 
Survival (IgG1) 
AMR (IgG3) 
 
 
 
 
- 
 
- 
- 
 
* or Nude rat recipients 
† - consistent with the fact that accommodation is due to loss of antigen expression by graft in primary recipient, which re-appears after re-
transplantation into second animal 
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C4b2a
C1q/r/s
C4
C2
C5b/6/7/8/9
(membrane attack 
complex)
Anti-donor Ab
C3b [(iC3b)
d/g]
C3a
C5a
C3 / C5
FcR
C3aR/5aR
CR1-CR4
C5b
Key
Figure 1
SIGNAL
Classical 
pathway 
activation
Cleavage of C5 and 
generation of membrane 
attack complex
Direct signalling by 
antibody and/or 
C3a/C5a
Recruitment and activation of 
innate effector cells via FcR 
and CR
Mechanisms of injury induced by complement activation
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•Low titre antibody for 
sustained period
•High titre antibody
•Uncontrolled activation of 
complement
•Thrombosis
•Graft failure
Graft accommodation
•Upregulation of complement regulators
•Expression of cytoprotective proteins
•Resistance to AMR
•Controlled antibody exposure
•Inhibition of systemic complement
activation 
OR
Antibody-mediated
rejection
Figure 2
Activated complement
Terminal components of 
complement inhibited
Activated EC
Resistant EC
Anti-donor Ab
Key
Membrane complement regulators
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Transplant Accommodation – Are the lessons learned from 
xenotransplantation pertinent for clinical allotransplantation? 
 
 
Anthony Dorling FRCP PhD 
Medical Research Council Centre for Transplantation & 
Innate Immunity Section, 
Division of Transplantation Immunology and Mucosal Biology 
King’s College London 
Guy’s Hospital 
Great Maze Pond 
London 
SE1 9RT 
 
Tel: +44 20 7188 5880 
Fax: +44 20 7188 5660 
Email: anthony.dorling@kcl.ac.uk 
 
 
Running title – transplant accommodation in xenografts 
Key words: Accommodation, Antibody Mediated Rejection, Complement,  
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Abstract 
‘Accommodation’ refers to a vascularized transplant that has acquired resistance to 
antibody-mediated rejection (AMR). The term was coined in 1990 (1), but the 
phenomenon was first described after clinical ABO-incompatible (ABOi) renal 
transplantation in the 1980s (2) and is recognised as a common outcome in this 
context today. Because of the absence, until recently of reliable animal models of 
allograft accommodation, it has been studied extensively by investigators in the 
xenotransplantation field.  With recent advances in the ability to recognise and 
diagnose AMR in human organs, the growth of desensitization programmes for 
transplantation into sensitised recipients and the availability of therapies that have 
the potential to promote accommodation, it is timely to review the literature in this 
area, identifying lessons that may inform preclinical and clinical studies in the future.  
 
Introduction: Endothelial cell activation and accommodation in 
xenotransplantation. 
The current paradigm of AMR places ‘endothelial cell activation’ at the heart of the 
pathophysiological process. This concept was first explored by Pober and colleagues 
in the 1980s, when defining how cytokines such as IL-1 influenced the interaction 
between endothelium and T cells (3). Extending the idea to humoral processes in 
xenotransplantation, it was proposed that changes in endothelial cell phenotype, 
such as chemokine and cytokine release, change in shape and loss of protective 
molecules (for example anticoagulants) bound to heparan sulphate, were integral to 
the pathology of AMR (1). In the context of pig-to-primate transplantation, the factors 
initiating these changes were primate IgM anti-pig antibodies (Abs) followed by 
complement activation via the classical pathway. Since hyperacute AMR was a 
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significant hurdle in the early 1990s, these and other insights had an important 
influence on subsequent developments in the field.  
Occasionally, pig organs survived and functioned (1, 4) despite the presence of high 
titre xenoreactive Ab in the circulation and complement deposition in the graft (5); 
these organs were described as having ‘accommodated’. Acknowledging that similar 
phenomena had been recognised and described (though not investigated) in clinical 
ABOi and HLA incompatible transplantation (1), Platt et al proposed that engineering 
a state of ‘accommodation’ would be a useful strategy for clinical 
xenotransplantation. Investigations in pursuit of this goal over the last 20 years have 
yielded a significant understanding of the mechanisms involved, though have yet to 
impact clinically. 
Of the three mechanisms originally proposed to explain accommodation (1), the first 
was that endothelial cells developed a resistance to injury during the post-transplant 
period; the second was that Abs post-transplantation had an altered affinity and/or 
specificity for the graft, compared to those pre-transplant and the third suggested 
that the antigenic epitopes on the graft were changed during transplantation, such 
that Ab could no longer bind.  Of these, 1 and 3 refer to changes in the donor organ  
(‘graft accommodation’) whereas 2 describes a change in the recipient (‘host 
accommodation’) and is an example of modulation of the anti-donor immune 
response. 
 
Antibody-mediated rejection in xenotransplantation – the importance of 
complement 
Evidence suggests that complement plays a critical role in xenograft AMR. In some 
rodent models (for instance the discordant guinea pig-to-rat), complement is 
Page 31 of 54
ScholarOne support: (434) 964 4100
American Journal of Transplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
IN SUBMISSION
 - 4 - 
activated by the alternative pathway (i.e. independently of Abs), though this is 
thought to be unrepresentative of the situation in preclinical pig-to-primate models. 
Two other commonly used rodent models involve transplanting hearts from hamsters 
or mice into rats. These are concordant models; in other words, rats have no pre-
existing anti-mouse or anti-hamster Ab (AHAb), so transplanted hearts are not 
rejected hyperacutely.  Instead, Abs develop by both T-dependent and T–
independent mechanisms resulting in AMR within 3-5 days.  
Ciclosporin (CsA) completely suppresses T cell activation in these models. 
Therefore, CsA-treated rats fail to make T-dependent IgG, but grafts still suffer AMR 
within the first week due to T-independent IgM production (6). However, co-
administration of CsA and cobra venom factor (CVF), to inhibit complement 
activation prevents rejection, and hearts in up to 75% of recipients survive long-term 
(as long as CsA is given), illustrating how important complement-fixation is for AMR 
in these models. Targeting the terminal complement components, using for instance 
a mAb against C6, has the same inhibitory effect as CVF.  Additionally, AMR does 
not occur when hearts are transplanted into C6-deficient rats, indicating that 
preventing assembly of the membrane attack complex is sufficient to inhibit AMR (7). 
This highlights that, of the potential mechanisms through which complement may be 
acting, generation of membrane attack complex is most important (figure 1) and 
early cascade molecules such as the anaphylotoxins C3a/C5a, have little role in 
these models. 
In another model, hearts from Lewis rats are transplanted into recombinase 
activating gene (RAG)- and Galactosyl-transferase double KO mice.  
Galactosyltransferase is the enzyme responsible for catalysing the addition of a 
terminal galactose through an α(1-3) linkage onto the carbohydrate chains of 
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glycoproteins, the moiety identified as the major xenoantigen recognised by human 
anti-pig Abs.  Passive transfer of mAbs against the α(1-3)gal epitope (8) induces 
AMR which is complement-dependent, even when the mAb fixes complement poorly 
in vitro (9) though in these circumstances, innate effector cells and FcR-dependent 
mechanisms are also involved (10) (figure 1).  
In pig-to-primate models, the importance of complement has been established by the 
resistance to AMR offered by organs from transgenic pigs expressing human 
regulators of complement activity (11).  Two points deserve further mention. The first 
is that vascularised pig organs have an enhanced susceptibility to the pathological 
effects of primate complement, not because of the originally proposed ‘homologous 
restriction’ of complement regulators (12), but because of distinct differences in the 
distribution of complement regulators, particularly the membrane attack complex 
inhibitor CD59 in pig vs. primate vasculature (13). This profound lack of regulation is 
not a problem in human allogeneic transplantation, though the strong association 
between AMR and C4d deposition and the recently reported success of the anti-C5 
monoclonal eculizumab in treating clinical AMR indicate that complement activation 
is nevertheless relevant clinically. The second point is that pig organs are susceptible 
to complement-independent AMR which is initiated by anti-pig alone (14, 15), so that 
inhibition of complement in pig-to-primate xenotransplantation is insufficient, without 
other measures, to prevent AMR.  Whether complement-independent AMR occurs in 
human clinical transplantation is a subject of intense interest.  
 
Accommodation in Rodent models 
In the hamster/mouse-to-rat models, complement only needs to be inhibited during 
the first week to prevent AMR (16, 17). An identical ‘naïve’ heart, transplanted after 
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this time undergoes AMR, indicating that the recipient has Abs and complement 
capable of causing rejection (18). Thus the first heart has acquired resistance to 
these Abs and this is classical graft accommodation. There is no complement-
independent AMR in these models;  additionally, accommodated hearts are resistant 
to rejection by passively administered Abs and many survive after re-transplantation 
into CsA-treated rats without CVF (19). Accommodation does not manifest in 
recipients given CVF without CsA, illustrating that effective suppression of T cells 
and elicited T-dependent Ab production is required for accommodation to occur (17, 
19). 
However, as first indicated by Hasan et al, accommodation does not occur when all 
anti-donor Ab production is suppressed (20-22). Moreover, passively transferred Ab 
prevented from causing AMR by CVF, can induce resistance to AMR in hamster 
hearts. Several studies since have shown the same (6, 19, 23-26) and have defined 
conditions in which graft accommodation can be achieved without manipulation of 
complement (23).  All these data are summarised in table 1. The indication is that Ab 
binding to the graft is necessary for graft accommodation.  
Transplanted ‘second’ xenografts grafts can accommodate, but the ease with which 
it happens depends on the context of the initial sensitisation.  Recipients sensitised 
by rejecting a first heart transplanted under cover of CsA (without CVF) develop 
sensitised T-independent B cells and CVF administered at the time of the second 
transplant can promote long-term survival. However, rats sensitised in the absence 
of any immunosuppression sensitise T and B cells and reject a second heart within 
minutes (27) even with CVF.  In these animals, CVF and CsA need to be 
administered together with exchange transfusion prior to the second transplant (to 
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reduce Ab titres) and splenectomy or ciclophosphamide to delay the return of elicited 
Abs.  
Therefore the fundamental condition required to allow spontaneous accommodation 
in these models is controlled exposure of the graft endothelium to anti-donor Ab 
post-transplantation (figure 2). The most logical explanation of why CVF is required 
in many models is that it prevents AMR in the context of rising Ab titres, thus allowing 
time for accommodation to develop.  For the same reason, accommodation is only 
seen when there is adequate suppression of T cell responses. Recent studies in 
allogeneic mouse transplant models have confirmed similar requirements to promote 
the long term survival and accommodation after transplantation into allosensitised 
recipients (28, 29). 
 Alternative models of accommodation 
Transgenic expression of tethered anticoagulants on the endothelium of mouse 
hearts makes them resistant to AMR after transplantation into rats and with CsA, 
they survive long-term without chronic rejection (30).  The resistance is not just due 
to the inhibition of thrombosis, but also to inhibiting thrombin signalling, which inhibits 
local (donor) CCL2 chemokine gradients, without which rat leukocytes are unable to 
infiltrate the organ (31, 32).  The importance or relevance of these data to other 
models of graft accommodation has not been determined.  
 
Phenotype of graft accommodation 
The above data suggests that accommodation is time-dependent and requires a 
specific interaction between the graft endothelium and low titre anti-donor antibodies. 
This section considers the phenotypic changes in the vasculature that result. 
 Reduced expression of antigenic epitopes. 
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Accommodation after leflunomide represents a special case, in that hearts show no 
binding of anti-donor Ab or complement on histology (25), compared to second naïve 
hearts which do (and are rejected by AMR).  Therefore accommodation is due to 
reduced expression of xenoantigens in the graft, most likely due to the direct effect of 
the drug.  
 Enhanced regulation of complement 
Accommodation induced in rat hearts by low titre IgG1 anti-gal Ab is characterised 
by significant upregulation of membrane bound complement regulators decay 
accelerating factor, Crry and CD59 (26), accompanied by increased deposition of the 
C3 breakdown product C3d compared to controls, suggesting enhanced functional 
regulation of complement activation on the donor endothelium. Similar features have 
been defined in accommodated pig organs after transplantation into baboons (33) or 
Galactosyltransferase KO pigs (34). 
Supporting the hypothesis that these changes were due to the anti-donor Ab, the 
accommodating IgG1 anti-gal Ab induced increased expression of the same 
complement regulators by rat endothelial cells in vitro and induced resistance to 
complement-mediated lysis (26). Other groups have reported similar findings using 
porcine endothelial cells in vitro (35), and shown that direct signalling though an 
NfKB-independent pathway is involved (36, 37) in a time-dependent, concentration-
independent manner (38).   
As elegantly demonstrated by Shimizu et al (39), enhanced expression of 
complement regulators on the donor organ increases the threshold for AMR, so this 
aspect of the accommodated phenotype has functional significance and is the basis 
of the resistance to AMR after passive transfer of Ab (and the reason why CVF can 
be stopped after 1 week). However, resistance to AMR induced in this way is relative 
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not absolute, so accommodated hamster hearts are rejected after injection of large 
boluses of AHAb (16), and accommodated rat hearts are sensitive to IgG3 anti-gal 
Ab, which fixes complement more efficiently than the IgG1 (26). These data highlight 
the potential fragility of graft accommodation.  
 Expression of ‘cytoprotective’ proteins 
The vasculature of accommodated mouse hearts show expression of 
hemeoxygenase-1 (HO-1). This single protein is absolutely required for 
accommodation, best illustrated by experiments using HO-1-deficient mice (40). 
Elegant work by Soare’s group has demonstrated the mechanisms by which HO-1 
works, and in this context, carbon monoxide is important (41). Because HO-1 plays a 
role in regulating decay accelerating factor expression by mouse endothelium (42), 
part of its importance in vivo may be through this effect. HO-1 is also upregulated 
during AMR, so it is not a biomarker of the accommodated state. Instead, it appears 
to be critically involved in the cellular response to multiple stress stimuli, so should 
be regarded as permissive for accommodation rather than a specific mediator. 
In accommodated hamster organs other cytoprotective proteins such as A20, Bcl-2 
and Bcl-xL (18, 19, 23, 27, 43) are also found in association with reduced rates of 
apoptosis compared to controls. There is considerable evidence that these proteins 
are induced in vitro in porcine and human endothelial cells by low (but not high) titre 
Abs against multiple epitopes, including MHC (23, 37, 44), by a nitric oxide 
dependent process (45) involving signalling through adenosine A2 receptors (44) 
and AKT (46, 47). This suggests that, unlike for HO-1, these proteins may be 
specifically involved in accommodation. In support of this, BcL-xL expression by 
peritubular and glomerular capillaries has been described as a specific marker of 
accommodation in biopsies taken within the first week after transplantation into HLA-
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sensitised recipients (48). Although the functional importance of these molecules in 
vivo has not been established, they are postulated to limit the vascular response to 
inflammation, by inhibiting NFkB activation. The absence of complement-
independent AMR in rodent and pig-to-primate models, implying suppression of the 
mechanisms driving this type of rejection, would support this hypothesis. 
Other molecules with cytoprotective function have been identified in accommodated 
porcine organs (33) and human ABOi renal transplantation (49), including heparan 
sulfate, syndecan-4-phosphate (both of which interact with anti-inflammatory 
moieties such as antithrombin for example (50)), Muc-1 and members of the tyrosine 
kinase receptor family.  
 
Relationship between graft and host accommodation and immune tolerance. 
In a contrived but elegant allogeneic model involving Galactosyltransferase KO 
mouse recipients, bone marrow reconstitution, injection of memory B cells specific 
for the α(1-3) gal epitope (51-53) and rechallenge with α(1-3) gal epitopes at variable 
times after transplantation of a wild-type heart, host rather than graft accommodation 
was shown to develop, the basis of which was predominant production of IgG2b, 
non-complement fixing antibodies, which bound the graft but did not cause AMR.  
These were dependent on the timing of rechallenge; too early and complement-fixing 
IgG2a were made (causing AMR); too late and anti-gal Ab production was 
completely suppressed indicating the recipient animals had become fully tolerant to 
the α(1-3) gal epitope present on the graft.  These data suggest that host 
accommodation and tolerance are related. 
In this model system, the transferred memory B cells were reliant on (absent) T cell 
help to generate new Abs against the α(1-3) gal epitope, whereas in many 
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xenogeneic models, B cells function independently.  Accordingly, the reports of ‘host 
accommodation’ in xenogeneic systems are limited. Komori et al, using tacrolimus 
and post-transplant splenectomy (day 1) reported that, alongside evidence of graft 
accommodation in hamster hearts, there was a significant reduction in circulating rat 
AHAb levels compared to controls (54).  Because accommodated hearts were 
rejected quickly when re-transplanted into naïve, tacrolimus-treated hosts and 
second naïve hearts were accepted by recipients with an accommodated heart, host 
accommodation was thought to be predominant in this model.  Leflunomide appears 
to promote both graft accommodation and tolerance, depending on it’s length of 
administration; after 4 weeks, it causes permanent suppression of the T-independent 
B cell response (25), so that rats transplanted with a second hamster heart accept 
them without rejection. In contrast, if administered for only two weeks it causes graft 
accommodation (see above). There is evidence from this model that only organs 
showing signs of graft accommodation are adequately protected against chronic 
rejection (55, 56). 
In CVF-based accommodation, host accommodation is less convincing. 
Accommodated hamster hearts may contain rat leukocytes preferentially expressing 
Th-2 cytokines such as IL-4, IL-13 and IL-10 (16), in association with skewing of rat 
IgG subclasses, changes which have been reported to impact favourably on the 
survival of second hearts, suggesting an influence of host accommodation on 
outcomes, but these findings have been contradicted (57).  Nevertheless, in vitro 
studies indicate that porcine endothelial cells incubated with human anti-pig Abs 
induce preferential Th-2 cytokine responses from human T cells (58), though the 
relevance of this in vivo is unclear. In accommodated mouse hearts, the expression 
of HO-1 is potentially capable of several direct effects on the recipient immune 
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system, such as reducing proliferation and IL-2 production and inducing activation-
induced cell death in CD4+ T cells (59, 60), and promoting regulatory T cells (61) 
and isolated HO-1 expression by the donor can influence the host immune response 
(62), but the relevance of these effects has not been established.  
 
Summary and conclusions. 
Rodent and pig-to-primate xenograft models have been used extensively to study the 
phenomenon of accommodation, with the majority of data indicating that 
accommodated grafts have a characteristic phenotype, which can arise 
spontaneously if either systemic complement activation (beyond C5) is transiently 
inhibited or the graft is exposed to slowly increasing titres of Ab. In this context, the 
active resistance to endothelial cell activation that develops involves increased 
expression of complement regulators, to reset the threshold of Ab required to initiate 
AMR, and cytoprotective proteins, postulated to prevent other elements of 
endothelial cell activation, particularly that due to NFkB activation. Organs that 
undergo such changes appear resistant to both AMR and chronic Ab-mediated 
rejection. Previously sensitised T and B cells have a significant impact on the ease 
with which accommodation occurs, so an important and necessary element in all 
accommodation induction protocols is effective control of recipient adaptive 
responses, such that T cell mediated rejection is inhibited and T-dependent B cell 
responses are controlled. 
These insights have obvious relevance for human clinical allotransplantation. The 
shortage of organs is driving increasing numbers of ABOi transplants after which 
accommodation appears to be common. However, few studies have investigated the 
phenotype of these organs and there is a paucity of knowledge about how this 
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important state arises.  Early work showing the continued presence of donor blood 
group antigens (63)  and the presence of C4d deposits in the vasculature of many 
biopsies indicates that the accommodation in these grafts resembles that seen in the 
classical models of xenograft accommodation.  
After HLA desensitisation, accommodation is thought to be uncommon, though it 
was described in a small series of patients from the 1990s (48). These patients 
received pre-transplant cyclophosphamide, sometimes for a prolonged period prior to 
transplantation, an agent rarely used nowadays. Whether this was important is 
difficult to know, but it is a possibility. For the modern day, clinical interventions to 
promote accommodation in this group of patients are now available.  From the 
understanding of xenogeneic systems, the most logical strategy would be to control, 
but not inhibit, the interaction between the graft and circulating Ab in the immediate 
post-transplantation period. The high incidence of C4d+ AMR in these patients 
suggests that inhibition of systemic complement activation for a short period post-
transplantation with Eculizumab would be useful and there are now agents to 
improve control of adaptive responses and to manipulate the induced antibody 
response, by selectively targeting B cells (Rituximab) and/or plasma cells 
(Bortezomib). However, aside from their use in isolated cases (64), all of these have 
yet to be systematically tested in rational protocols designed to promote 
accommodation. 
As there are no validated markers of human accommodation (besides C4d in the 
absence of pathology on the graft biopsy), a major question will be how to recognise 
spontaneous accommodation when it has occurred?. Two other questions are 
important to address if we are to develop ways to engineer accommodation (rather 
than allow it to occur spontaneously). These are what is the mechanism 
Page 41 of 54
ScholarOne support: (434) 964 4100
American Journal of Transplantation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
IN SUBMISSION
 - 14 - 
underpinning the resistance to AMR  and do accommodated organs promote 
immune modulation in the recipient? Using the knowledge gained from studying 
xenografts as a place to start, well-designed studies in selected human recipients 
could address these and other important questions. 
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Figure 1 legend  
Diagram to illustrate the potential mechanisms of injury induced by complement 
activation.  In models of xenogeneic AMR, the generation of membrane attack 
complex is most important. 
 
Figure 2 legend 
Diagram to illustrate the events at the endothelium during antibody-mediated 
rejection vs. graft accommodation.  
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EDITORIAL COMMENTS:  
none  
 
REVIEWER COMMENTS:  
Reviewer: 1  
Comments to the Author  
The revised manuscript addresses many of the suggestions and is improved. 
I would suggest a few minor revisions.  
 
1. Abbreviations should be eliminated wherever possible. EC will not be 
known to some readers and XNA, RCA will be known by very few. 
Abbreviations used only once or twice such as WT should be eliminated even 
if known.  
 
I have removed these abbreviations and others as suggested by the reviewer 
 
2. The author might wish to use some term other than XNA to refer to the 
antibodies that cause acute rejection of xenografts. While these antibodies 
might recognize aGal, it is not clear they are natural, as opposed to elicited 
and some of the antibodies are clearly elicited by non-aGal antigens. 
 
I have removed the term and replaced with various, such as human anti-pig 
or xenoreactive antibody 
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